BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Best Amusement Park Bite: What Do You Very much want to Crunch On? - 2Survey: Canteen Cups With Great Warm Protection Impact
- 3Banks for High Fixed Store Rates: Amplify Your Reserve funds
- 4PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- 5Texas cities have some of the highest preterm birth rates in the US, highlighting maternal health crisis nationwide
- Scientists document a death from a meat allergy tied to certain ticks
- Instructions to Decide the Best SUV Size for Seniors
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- The most effective method to Recognize a Great Lab Jewel
- Share your pick for the riding area that characterizes your surf undertakings!
- Vote in favor of Your Number one BWM Vehicles
- China's Normal Ponders: A Visual Excursion
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
